Vaximm AG Announces Phase 2a Trial Results for VXM01
In a significant breakthrough, Vaximm AG has revealed promising data from its Phase 2a clinical trial of VXM01 combined with Avelumab, targeting glioblastoma. This innovative therapy aims to enhance safety and tolerability in patients battling this aggressive form of cancer.
Trial Overview and Results Highlights
The Phase 2a trial focused on evaluating the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, along with Avelumab, a PD-L1 inhibitor. It marked a collaboration with Merck KGaA, enhancing the therapeutic potential for patients with recurrent glioblastoma.
The primary outcome from the trial showcases that the VXM01-avelumab combination was generally well tolerated. Most adverse events encountered were mild to moderate, consistent with previous reports on Avelumab alone. Importantly, there were no serious adverse events attributed to VXM01, reinforcing its manageable safety profile, particularly among a frail patient demographic.
Key statistical findings from the trial unveiled a 12.0% objective response rate (ORR) in the cohort of non-resected patients. Among them, 12.0% exhibited partial remission while 4.0% had stable disease. This underpins the potential clinical benefit of combining VXM01 with PD-L1 inhibitors like Avelumab for patients with such challenging conditions.
Survival Outcomes and Tumor Response
Despite the relatively small sample size of 25 participants, the trial yielded encouraging results. The median time to progression was observed at 2.7 months with a range extending from 0.3 to 22.1 months. Furthermore, the median overall survival (OS) reached 11.1 months, showcasing a much longer duration than the median PFS typically associated with recurrent glioblastoma patients.
Moreover, noteworthy reductions in tumor size were documented among responding patients, demonstrating that VXM01 could be effective against tumors of varying sizes. This includes patients with larger tumors, thereby broadening the scope of candidates who may benefit from this therapy.
Importance and Future Directions
Moving forward, Vaximm AG highlights the necessity for continued research in this domain. The favorable safety and tolerability data encourage further exploration into VXM01’s ability to incite a VEGFR-2 specific immune response, which could enhance therapeutic outcomes in glioblastoma therapy.
Dr. Constance Hoefer, CEO of Vaximm AG, stated, "This Phase 2a trial's completion represents a significant milestone. We are optimistic about these initial findings, with a commitment to advancing VXM01 for glioblastoma and other malignancies despite challenges. Our objective remains clear: to enhance treatment outcomes for patients battling this relentless disease."
About VXM01 and Its Mechanism of Action
VXM01 operates as an oral T-cell immunotherapy developed to expertly activate T-cells, enabling them to attack not just tumor cells but also the tumor vasculature. Its backbone is a live attenuated bacterial vaccine strain, carefully modified to carry the VEGFR2 gene, leading to an immune response targeting the tumor's blood supply.
This immunity-generating approach activates specific cytotoxic T-cells that excel at destroying tumor blood vessels, thereby facilitating a stronger immune cell infiltration into the tumor itself. Such promising preclinical outcomes have suggested that VXM01 may elicit robust anti-tumor effects across various cancer types, including glioblastoma.
About Vaximm AG and OSR Holdings Inc.
As a pioneering force in biotechnology, Vaximm AG is dedicated to creating revolutionary immunotherapies. Their innovative strategies seek to harness the potential of cancer vaccines to efficiently address patients' needs facing various cancer challenges.
OSR Holdings, Inc. (NASDAQ: OSRH) represents a global drive toward improving healthcare outcomes and enhancing patient quality of life. With a focus on innovative treatments across multiple therapeutic areas, OSR is committed to building a strong portfolio of healthcare solutions that meet the evolving needs of patients and the healthcare landscape.
Contact:
Vaximm AG
For more information, please visit www.vaximm.com.
Frequently Asked Questions
What were the main results of the Phase 2a trial?
The trial shows the VXM01 and Avelumab combination therapy was generally well-tolerated, with 12.0% of non-resected patients achieving partial remission.
How does VXM01 work in treating glioblastoma?
VXM01 activates T-cells to target both tumor cells and the tumor's blood supply, using a modified bacterial vaccine strain for its therapeutic effect.
What is the significance of the trial's safety data?
Safety data indicated that the combination therapy was well tolerated, with no serious adverse events linked to VXM01, highlighting its manageable risk profile.
Why is further research needed for VXM01?
Further research is crucial to explore the potential immune response VXM01 can generate and its effectiveness for specific patient groups with glioblastoma.
What is the vision of OSR Holdings Inc.?
OSR Holdings aims to create a comprehensive portfolio of innovative therapeutic solutions to improve healthcare outcomes and quality of life for patients globally.
